Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?

Jonggi Choi; Won-Mook Choi; Young-Suk Lim

doi:10.1016/j.cld.2023.05.005

Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?

Clin Liver Dis. 2023 Nov;27(4):809-818. doi: 10.1016/j.cld.2023.05.005. Epub 2023 Jun 30.

Authors

Jonggi Choi¹, Won-Mook Choi¹, Young-Suk Lim²

Affiliations

¹ Department Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.
² Department Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea. Electronic address: limys@amc.seoul.kr.

PMID: 37778771
DOI: 10.1016/j.cld.2023.05.005

Abstract

In treatment-naïve patients with chronic hepatitis B virus (HBV) infection, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide have a minimal or no risk of drug-resistance. These 3 nucleos(t)ide analog agents are highly potent inducing high rate of virologic response (reducing serum HBV DNA to levels undetectable by polymerase chain reaction assays) in most treatment-naïve patients. Our randomized trials have demonstrated that monotherapy with TDF can provide a successful virological response in most of the heavily pretreated patients with multidrug resistance to ETV or adefovir.

Keywords: Adefovir; Entecavir; Hepatitis B; Hepatocellular carcinoma; Lamivudine; Tenofovir.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / adverse effects
Drug Therapy, Combination
Hepatitis B virus / genetics
Hepatitis B, Chronic* / drug therapy
Humans
Tenofovir / therapeutic use
Treatment Outcome

Substances

Antiviral Agents
Tenofovir